Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Human aging is associated with increased fat mass, insulin resistance and systemic inflammation. In addition to overall increases in fat mass, accumulation of lipid in such insulin-sensitive tissues as liver and skeletal muscle appears to contribute importantly to insulin resistance. Furthermore, age-related decreases in muscle mitochondrial ATP production rate and mitochondrial DNA copy number are likely to contribute to impaired insulin-mediated glucose disposal, as well as decreased muscular endurance and activity levels. Additionally, systemic inflammation is now believed to contribute to insulin resistance and thus ultimately to many age-related disorders, including diabetes mellitus, Alzheimer's disease, atherosclerosis and many cancers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Albert Einstein College of Medicine; Albert Einstein College of Medicine of Yeshiva University
• Treatments: Resveratrol

Criteria

Inclusion Criteria:

• BMI: 26-35

• Non-smoker

• Normal screening labs (CMC, chemistry, LFTs PT/PTT)

• No CAD

• Good IV access

Exclusion Criteria:

• High cholesterol

• <4 week history of participation in another drug trial

• Severe hypertension

• Heart disease

• Liver disease of liver abnormalities

• Cerebrovascular disease, i.e. stroke

• CVD

• Seizures

• Bleeding disorders

• Muscle disease

• Cancer

• HIV

• Hepatitis (all types)

• Mentally disabled persons

• Pregnant women

• Allergies to Novocaine, Lidocaine, Benzocaine

• Subjects on the following medications:

• Anticoagulant and antiplatelet drugs

• Anti-epileptic drugs

• Mexiletene

• Quinidine

• Cyclosporine

• Tacrolimus

• HIV protease inhibitors